calendar

5,901 catalysts · 5,901 phase readout · 2,300 8k filing · 413 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view export CSV

next 91 dayslessmore

MonWedFri

view

agenda month

show past →

sort

soonest latest type sponsor alpha

type: drug expiry type: phase readout clear all

Date TBD

1

ACTIVE_NOT_RECRUITINGphase readoutNCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Phase: PHASE2. Conditions: Lymphoma, Large B-Cell, Diffuse

full page →ctgov ↗

← prev

page 119 of 119

next →